Prognostic value of serum creatine level in patients with vulvar cancer.

Richard Schwameis, Magdalena Postl, Christine Bekos, Lukas Hefler, Alexander Reinthaller, Veronika Seebacher, Christoph Grimm, Stephan Polterauer, Samir Helmy-Bader

Journal: Scientific reports 2020;9(1):11129

PMID: 31366905

Abstract

Vulvar cancer is a rare malignancy with poor prognosis that generally occurs in elderly patients. The individual prognosis is difficult to assess. Serum creatinine levels are frequently elevated in elderly patients. Recent evidence have shown shown that - besides indicating kidney impairment - serum creatinine levels may be used to predict the survival in cancer patients. Several studies observed an association between elevated serum creatinine levels and poor prognosis in patients with solid tumors. In this retrospective cohort study, serum creatinine levels were evaluated in 170 patients with invasive vulvar cancer. Serum creatinine levels were correlated to established clinicopathologic factors. Univariate and multivariate survival analysis were performed. Elevated serum creatinine levels (>1.2 mg/dl) were significantly associated with both poor disease specific and overall survival. Three year overall survival rates were 74.8% and 32.5% for patients with serum creatinine levels of ≤ and >1.2 mg/dl, respectively. In a multivariate survival model, serum creatinine levels were significantly associated with overall survival independent of tumor stage and patients' age. In conclusion, pretherapeutic serum creatinine levels may be useful as an independent prognostic parameter in patients with vulvar cancer.

Address: Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Department of Gynecology, Ordensklinikum Linz, Seilerstätte 4, 4020, Linz, Austria.; Karl Landsteiner Institute for Gynecologic Surgery and Oncology, Seilerstaette 4, 4020, Linz, Austria.; Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.